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AbstrACt
Objective Morphine is frequently used in acute coronary 
syndrome (ACS) due to its analgesic effect, it being 
recommended in the main cardiology guidelines in Europe 
and the USA. However, controversy exists regarding its 
routine use due to potential safety concerns. We conducted a 
systematic review of randomised-controlled trials (RCTs) and 
observational studies to synthesise the available evidence. 
Design Systematic review and meta-analysis.
Data sources CENTRAL, MEDLINE, EMBASE and trial 
registries.
Eligibility criteria for selecting studies We included 
RCTs and observational studies evaluating the impact of 
morphine in cardiovascular outcomes or platelet reactivity 
measures.
Data extraction and synthesis Data were screened, 
extracted and appraised by two independent reviewers. The 
data were pooled results using a random-effects model. 
Outcomes included in-hospital mortality, major adverse 
cardiovascular events (MACE), platelet reactivity (using 
VerifyNow) and bleeding, reported as relative risk (RR) with 
95% CI. We assessed the confidence in the evidence using 
the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) framework. We followed the Meta-
analysis Of Observational Studies in Epidemiology and 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines.
results Five RCTs and 12 observational studies were 
included, enrolling 69 993 participants. Pooled results 
showed an increased risk of in-hospital mortality (RR 1.45 
[95% CI 1.10 to 1.91], low GRADE confidence), MACE 
(RR 1.21, 95% CI 1.02 to 1.45) and an increased platelet 
reactivity at 1 and 2 hours (59.37 platelet reactivity units 
[PRU], 95% CI 36.04 to 82.71; 68.28 PRU, 95% CI 37.01 to 
99.55, high GRADE confidence) associated with morphine. 
We found no significant difference in the risk of bleeding. 
We found no differences in subgroup analyses based on 
study design and ACS subtype.
Conclusions Morphine was associated with an increased 
risk of in-hospital mortality and MACE but the high risk 
of bias leads to low result confidence. There is high 
confidence that morphine decreases the antiplatelet effect 
of P2Y12 inhibitors.
PrOsPErO registration number CRD42016036357.
IntrODuCtIOn   
Worldwide, cardiovascular events are the 
leading cause of death.1 The burden of disease 
will likely remain high2 3 as the incidence of 
cardiovascular events is expected to continue 
increasing.4
Antiplatelet agents (aspirin and P2Y12 
inhibitors), anticoagulants and coronary 
revascularisation are the mainstay in the early 
treatment of acute coronary syndrome (ACS), 
and their use likely improves prognosis.5–7 
In both Europe and the USA, morphine, a 
potent analgesic that is a competitive agonist 
of μ-receptors in the central nervous system 
and smooth muscle, is recommended for pain 
control in the ACS setting.7 However, the acti-
vation of opioid receptors in the myenteric 
plexus decreases gut motility and secretion, 
inhibiting the activation of P2Y12 inhibitors 
by decreasing their absorption and bioavail-
ability.8 There is conflict regarding the possi-
bility that morphine interferes with P2Y12 
inhibitors in the achievement of an adequate 
antithrombotic milieu,7 9 10 which may 
decrease the efficaciousness of antiplatelet 
drugs, if these are given concurrently with 
morphine. We conducted a systematic review 
of randomised-controlled trials (RCTs) and 
observational studies to evaluate the safety of 
morphine use in ACS, hypothesising that we 
would find a clinically meaningful result.
strengths and limitations
 ► We assessed data from both randomised trials and 
observational studies.
 ► The risk of bias across most observational studies is 
high, which raises concerns in pooling data with the 
far smaller randomised trials.
 ► To reduce the impact of the potential bias, before 
meta-analysis we adjusted the within-study vari-
ance–covariance matrix of observational studies at 
a critical risk of bias using a precision correction, 
a weight factor that provides more conservative 
pooled estimates.
 ► Key data were not adequately reported across many 
of the included studies.
 ► We used the Grading of Recommendations 
Assessment, Development and Evaluation approach 
to appraise the available evidence.
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MEthODs
This systematic review followed the reporting principles 
of Meta-analysis Of Observational Studies in Epidemi-
ology  and  Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses.11 12Patients and public were 
not involved in this review.
Eligibility criteria
We considered longitudinal studies (ie, RCTs and obser-
vational studies) evaluating the impact of morphine in 
cardiovascular outcomes or platelet reactivity measures. 
The target population was patients with ACS, which can 
be either ST-elevated myocardial infarction (STEMI) or 
non-ST elevated acute coronary syndrome (NSTE-ACS).13 
Studies had to evaluate morphine (irrespective of the 
administration route or dose) against placebo, control 
(no intervention arm) or any other analgesic non-opioid 
drug.
Primary outcomes were in-hospital mortality and major 
adverse cardiovascular events (MACE), as defined by the 
PLATO trial (cardiovascular mortality, non-fatal MI or 
non-fatal stroke).14 Secondary outcomes comprised addi-
tional safety outcomes, as defined within the included 
studies (as reported in the original studies, including 
morphine-related adverse events such as bleeding, 
nausea/emesis, bradycardia, hypotension and respiratory 
insufficiency) and platelet reactivity (a pharmacodynamic 
outcome, sought through the VerifyNow method, which 
is the most widely used assay to evaluate platelet reactivity 
and shows a stronger correlation with MACE in ACS than 
other methods, namely multiple electrode aggregometry 
(MEA)/Multiplate10 15). VerifyNow is a blood test that 
measures platelet reactivity by the rate and extent of light 
changes in whole blood as platelets aggregate, and there-
fore measures platelet response to major antiplatelet 
agents.16
Information sources and search method
Potentially eligible studies were identified through an 
electronic search of CENTRAL (Cochrane Library), 
MEDLINE, EMBASE, and  clinicaltrials. gov from incep-
tion to November 2018 (online supplementary material). 
No language restrictions were applied. We cross-checked 
reference lists of reports for potential additional studies.
study selection and data collection process
Two reviewers (GSD and either FBR or ANF) inde-
pendently screened the titles and abstracts yielded by the 
search and assessed the full texts of the selected studies 
to determine the appropriateness for inclusion. Disagree-
ments were resolved through consensus or by a third 
reviewer (DC) serving as final arbitrator. The reasons for 
exclusion were recorded at the full-text screening stage.
Two reviewers (ANF and GSD) extracted study data 
following a pre-established data collection form. Data 
from studies’ plots were retrieved through Plot Digitizer 
V.2.6.8. When studies presented different estimates of 
the outcome of interest, we extracted the most precise or 
adjusted measures.
Risk of bias was independently evaluated by two 
authors (GSD and ANF) using different tools according 
to study design. For RCTs, we used the Cochrane risk 
of bias tool, where domains were qualitatively classified 
as at high, unclear or low risk of bias.17 The overall risk 
of bias for each RCT was divided as high or low risk, 
with high risk being those RCTs in which at least one 
domain was assessed at a high risk of bias, or more than 
three domains were had a rating of unclear. For obser-
vational studies we used the ROBINS-I tool, assessing 
the following domains: confounding, selection of partic-
ipants, classification of intervention, deviations from 
intervention, missing data, measurement of outcome 
and selection of reported results.18 These domains were 
qualitatively classified as at critical, serious, moderate or 
low risk of bias. The overall risk of bias for each obser-
vational study was divided as critical or non-critical, 
following ROBINS-I criteria. Risk of bias graphs was 
derived from these tools.
statistical analysis
We used OpenMetaAnalyst19 and Review Manager20 for 
statistical analysis and to derive forest plots. We used a 
random-effects model to pool data owing to the antici-
pated heterogeneity in the included trials, in particular 
differences in study design. We reported pooled dichot-
omous data using risk ratios (RRs) and continuous data 
the mean difference (MD), reporting 95% CIs and corre-
sponding p values for both. Heterogeneity was assessed 
using I.2 21 We present effect estimates as RR because rela-
tive estimates are more similar across studies with different 
designs, populations and lengths of follow-up than abso-
lute effects.22 When raw data or RR was unavailable, we 
used the HR or OR provided the estimate was small.23 24 
Preplanned subgroup analyses considering study design 
(RCTs and observational studies) and ACS type were 
conducted. A sensitivity analysis was also performed, in 
which RCTs at high risk of bias and observational studies 
at critical risk of bias were excluded from the analysis. 
Reporting bias was performed through funnel plot exam-
ination and statistical methods providing that a sufficient 
number of studies were included.25
When observational studies were assessed as having a 
critical risk of bias, we adjusted the within-study variance–
covariance matrix using a precision correction of 0.1 that 
will provide more conservative pooled estimates.26 27 This 
conservative weight factor was based on expert-based clin-
ical grounds.
We used the Grading of Recommendations, Assessment 
and Evaluation (GRADE) framework to report the overall 
quality of evidence. The certainty in the evidence for each 
outcome was graded as high, moderate, low or very low.28
Patient and public involvement
Patients and the public were not involved in this review.
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The search returned 1419 records, resulting in 1035 
records after removing all duplicates. After title and 
abstract screening, 53 articles were assessed for full-text 
screening, with 17 being included for qualitative and 
quantitative syntheses, 5 being RCTs29–33 and 12 being 
observational studies.10 34–44 We did not retrieve any 
unpublished study (figure 1).
The characteristics of the included studies can be seen 
in table 1 and table 2. Study publication dates ranged from 
1969 to 2018, with sample sizes between 12 and 57 039 
participants. The largest study, Meine et al,34 a retrospec-
tive cohort study, accounted for 81% of the participants 
in this review.
Morphine administration was variable across 
the included studies, with six of the observational 
studies10 34 35 40 42 45 not reporting information regarding 
dose and number or mode of administration. Among 
RCTs, morphine administration was intravenous or intra-
muscular at a dose between 2 and 10 mg, either in single 
or multiple administrations. The forms of antiplatelet 
therapy used across studies were varied, and firm conclu-
sions cannot be made.
risk of bias
We judged two of the five RCTs to be at a high overall risk 
of bias, one31 due to having unclear risk of bias in all but 
one domain, and the other29 due to a high risk of perfor-
mance and attrition bias. All observational studies were 
at risk of bias due to confounding, and all but one36 were 
at moderate risk of selection of study results. Grendahl 
and Hansteen38 was additionally at moderate risk of bias 
due to measurement of outcome. Overall, two observa-
tional studies were at critical risk of bias,34 35 seven were at 
serious risk of bias36 38 39 and three were at a moderate risk 
of bias10 37 40 (online supplementary material).
In-hospital mortality
Four RCTs (n=2237) and seven observational studies 
(n=63 112) contributed with data for this outcome. 
Adjusted pooled results showed an increased risk of 
in-hospital mortality in the morphine group (RR 1.45; 
95% CI 1.10 to 1.91; I2=0%; figure 2). Subgroup analysis 
Figure 1 Study flow diagram.
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based on study design (p=0.67 for interaction; figure 2) 
and ACS subtype (STEMI RR 1.05; 95% CI 0.57 to 1.94; 
I2=0%; NSTE-ACS RR 1.57; 95% CI 1.15 to 2.14; I2=0% 
and p=0.25 for interaction) were both non-significant. 
Sensitivity analysis by excluding studies at critical risk 
of bias showed no differences between morphine and 
control (RR 1.41; 95% CI 0.87 to 2.27; I2=0%; n=5872 
participants). The GRADE confidence in this estimate is 
low. 
MACE
Three RCTs (n=375) and seven observational studies 
(n=61 054) contributed with data for this outcome. 
Adjusted pooled results showed an increased risk of 
MACE in the morphine group (RR 1.21, 95% CI 1.02 to 
1.45; I2=0%; figure 3). Subgroup analysis based on study 
design (p=0.44 for interaction; figure 3) and ACS subtype 
(STEMI RR 1.20; 95% CI 0.71 to 2.03; I2=0%; NSTE-ACS 
RR 1.21; 95% CI 1.01 to 1.46; I2=0% and p=0.98 for inter-
action) were both non-significant. Sensitivity analysis by 
excluding studies at critical risk of bias showed no differ-
ences between morphine and control (RR 1.40, 95% CI 
0.85 to 2.30; I2=0%; n=1952). The GRADE confidence in 
this estimate is low.
bleeding
One RCT (n=70) and two observational studies (n=482) 
contributed with data for major bleeding, while three 
RCTs (n=375) and three observational studies (n=57 647) 
contributed with data for minor bleeding. No differ-
ences were found between morphine and control in 
the risk of either major (RR 0.62, 95% CI 0.18 to 2.12; 
I2=0%) or minor (RR 0.62, 95% CI 0.18 to 2.12; I2=40%) 
bleeding (online supplementary material). Subgroup 
analysis based on study design and ACS subtype were 
both non-significant (major bleeding: p=0.85 and p=0.85 
for interaction, respectively; minor bleeding: p=0.20 and 
p=0.20 for interaction, respectively). The GRADE confi-
dence in these estimates is low for major bleeding and 
very low for minor bleeding.
Platelet reactivity
We present data from 1 and 2 hours after morphine 
administration, as these are likely to be the most clini-
cally meaningful timepoints. Two RCT (n=82) and two 
observational studies (n=228) contributed with data for 
this outcome. One hour after administration, morphine 
was associated with increased platelet reactivity, with 
an MD of 59.37 platelet reactivity units (PRU) (95% CI 
36.04 to 82.71; I2=23%; figure 4). Two hours after admin-
istration, morphine remained associated with increased 
platelet reactivity (MD 68.28 PRU, 95% CI 37.01 to 99.55; 
I2=28%; figure 5). Subgroup analysis based on study 
design and ACS subtype were both non-significant at both 
timepoints (p=0.25 for interaction for both timepoints; 
p=0.24 for interaction for both timepoints, respectively). 
The GRADE confidence is high for this outcome at both 
timepoints.
We additionally pooled results using the three trials 
that reported results using the MEA method.30 39 40 These 
results were consistent with those using the VerifyNow 
Figure 2 Forest plot of in-hospital mortality according to morphine use, subgroups according to study design. IV, 
inverse variance; NSTE-ACS, non-ST elevated acute coronary syndrome; RCT, randomised controlled trials; STEMI, ST-elevated 
myocardial infarction.
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method at both 1 hour (MD 27.80, 95% CI 16.03 to 39.57, 
I2=24%) and 2 hours after morphine administration (MD 
19.99, 95% CI 1.52 to 38.46, I2=82%).
Additional outcomes
We found no differences associated with morphine use, 
namely regarding the risk of cardiogenic shock (RR 1.48; 
95% CI 1.00 to 2.18; I2=0%), heart failure (RR 1.17; 95% CI 
0.91 to 1.51; I2=33%), hypotension (RR 0.93; 95% CI 0.49 
to 1.74; I2=5%), nausea/emesis (RR 1.84; 95% CI 0.80 to 
4.23; I2=44%), respiratory insufficiency (RR 0.77; 95% CI 
0.31 to 1.91; I2=0%) or stent thrombosis (RR 1.13; 95% CI 
0.67 to 1.92; I2=0%) (online supplementary material).
DIsCussIOn
Our main findings were as follows: (1) morphine was asso-
ciated with an increased risk of in-hospital mortality and 
MACE; however, high risk of bias led to low confidence 
in the results; (2) morphine decreased the antiplatelet 
effect of P2Y12 inhibitors in the first hours of ACS, and 
Figure 3 Forest plot of MACE (major adverse cardiovascular events) according to morphine use, subgroups according to 
study design. IV, inverse variance; RCTs, randomised controlled trails.
Figure 4 Forest plot of platelet reactivity at 1 hour postmorphine administration, using the VerifyNow method, subgroups 
according to study design.IV, inverse variance; RCTs, randomised controlled trails. 
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the risk of bias associated with this objective measure was 
considered to be low.
Despite the widespread use of morphine in chest pain 
and anxiety relief in patients with ACS, conflicting data 
about its clinical impact has recently come to light.30 The 
activation of opioid receptors in the myenteric plexus 
decreases gut motility and secretion, inhibiting the acti-
vation of drugs whose action is directed at the P2Y12 
protein and decreasing its absorption and bioavailability. 
Moreover, morphine is also known for its proemetic and 
antiperistaltic effects, which can further contribute to the 
decreased absorption of antiplatelet drugs.
This systematic review was planned and designed to 
evaluate the safety outcomes associated with morphine 
use in ACS. Pooled data RCTs and observational studies 
showed that treatment with morphine in patients with 
ACS is associated with a significant increase risk of in-hos-
pital mortality, MACE and platelet reactivity.
We found that morphine decreased the antiplatelet 
effect of P2Y12 inhibitors in the first hours of ACS. 
The clinical significance of this increase is uncertain, 
as the magnitude of this change is less than the differ-
ence between ticagrelor and clopidogrel in ACS,46 but 
appears to be at least twice as large as the impact of 
esomeprazole on the pharmacodynamics of clopido-
grel.47 This effect of morphine ceases to be relevant 
at around the 8 hour mark.36 This may contribute to a 
delay in the onset of acute medical treatment, a greater 
prothrombotic milieu and more myocardial damage in 
patients with ACS. What is more, the analgesic effect 
of morphine followed by a decreased sympathetic 
response of the patient, without directly reversing the 
cause of ACS, may lead physicians to underestimate the 
severity of the underlying disease and to postpone the 
referral to an invasive revascularisation procedure. All 
the above-mentioned reasons may contribute towards 
the increased risk of in-hospital mortality and MACE 
related to the use of morphine. In clinical practice, 
other opioid analgesic drug such as fentanyl can be 
used, and a recent trial showed that fentanyl treatment 
in ACS increased platelet reactivity compared with no 
treatment. Although this suggests a possible class-effect 
of opioids on antiplatelet drugs, the evidence is sparse 
and requires further investigation before firm conclu-
sions can be made.48
Unexpectedly, we did not find an increased risk of 
nausea/emesis associated with morphine. This raises the 
likelihood that the reduction of gut secretion and motility 
is the core effect through which morphine decreases the 
activation of P2Y12 drugs.
With regard to platelet reactivity, we believe that the 
magnitude of the difference found supports a change in 
clinical practice, moving away from a recommendation 
to use morphine in ACS to recommending not using it 
routinely. The strength of this recommendation may be 
controversial due to the nature of the trials used and 
the other outcomes in this review not being statistically 
significant.
An important concern when combining randomised 
and observational data is the extent to which the partici-
pants and clinical setting are sufficiently similar to justify 
their pooling. On this account, the results of this review 
are robust since we found low heterogeneity across 
the outcomes of interest and the fact that none of the 
subgroup analyses comparing RCTs versus observational 
studies were statistically significant. Further proof of the 
consistency of the results is that no subgroup analysis 
showed a difference between STEMI and NSTE-ACS. 
However, due to concerns over risk of bias across studies, 
we assessed the certainty in the evidence as low, despite 
there being little concern regarding inconsistency, indi-
rectness or lack of statistical power.
Figure 5 Forest plot of platelet reactivity at 2 hours postmorphine administration, using the VerifyNow method, subgroups 
according to study design. IV, inverse variance; RCTs, randomised controlled trails. 
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The key limitation of this review comes from the 
key limitation of most observational research, namely 
confounding. In a conservative approach, we attempted 
to minimise the impact of observational studies and 
their bias in the estimates by applying a correction factor 
previously used in other meta-analysis.26 27 Nevertheless, 
we must recognise that this adjustment is artificial and 
limits our results. Another limitation regards the possible 
differences in the doses and route of administration of 
morphine that were not available in most of the included 
studies.
Physicians may administer morphine to patients with 
more severe forms of chest pain, which may correspond 
to a more severe underlying ACS. This means that the 
increased risk of negative clinical outcomes could come 
as a result of patients being given morphine, or, alterna-
tively, from the fact that morphine is usually reserved for 
the sickest patients. Because the included observational 
studies were substantially larger than the RCTs, including 
them in the meta-analysis could increase the risk of 
producing a biased result with an undue degree of statis-
tical precision. To minimise this risk, we used methods to 
decrease the weight given to the largest and most biased 
studies, providing a more conservative estimate based on 
the available evidence. In doing so, we have produced the 
first and only systematic review to date that evaluates this 
highly relevant clinical question.
COnClusIOns
This systematic review raises concern about the use of 
morphine in patients with ACS and challenge the current 
clinical recommendations for its use in ACS. Most data 
come from studies at high risk of bias when evaluating the 
true effect of morphine in this setting. As such, a low-bias, 
adequately powered RCT designed to evaluate this ques-
tion would be of significant scientific and clinical value. 
However, there is high certainty that morphine decreased 
the antiplatelet effect of P2Y12 inhibitors in the first 
hours of ACS.
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